NasdaqGS - Delayed Quote • USD
Atara Biotherapeutics, Inc. (ATRA)
At close: 4:00 PM EDT
After hours: 4:03 PM EDT
Earnings Estimate
| CURRENCY IN USD | Current Qtr. (Mar 2024) | Next Qtr. (Jun 2024) | Current Year (2024) | Next Year (2025) |
|---|---|---|---|---|
| No. of Analysts | 3 | 3 | 4 | 4 |
| Avg. Estimate | -0.26 | -0.14 | -0.72 | -0.46 |
| Low Estimate | -0.33 | -0.23 | -1 | -0.79 |
| High Estimate | -0.17 | -0.03 | -0.4 | -0.05 |
| Year Ago EPS | -0.72 | -0.68 | -2.61 | -0.72 |
Revenue Estimate
| CURRENCY IN USD | Current Qtr. (Mar 2024) | Next Qtr. (Jun 2024) | Current Year (2024) | Next Year (2025) |
|---|---|---|---|---|
| No. of Analysts | 3 | 3 | 4 | 4 |
| Avg. Estimate | 24.69M | 31.3M | 98.04M | 83.06M |
| Low Estimate | 15.5M | 16M | 40M | 16M |
| High Estimate | 31.57M | 40M | 170.18M | 128M |
| Year Ago Sales | 1.23M | 3.77M | 8.57M | 98.04M |
| Sales Growth (year/est) | 1,913.90% | 730.20% | 1,043.60% | -15.30% |
Earnings History
| CURRENCY IN USD | 3/31/2023 | 6/30/2023 | 9/30/2023 | 12/31/2023 |
|---|---|---|---|---|
| EPS Est. | -0.39 | -0.67 | -0.66 | -0.48 |
| EPS Actual | -0.72 | -0.68 | -0.66 | -0.56 |
| Difference | -0.33 | -0.01 | 0 | -0.08 |
| Surprise % | -84.60% | -1.50% | 0.00% | -16.70% |
EPS Trend
| CURRENCY IN USD | Current Qtr. (Mar 2024) | Next Qtr. (Jun 2024) | Current Year (2024) | Next Year (2025) |
|---|---|---|---|---|
| Current Estimate | -0.26 | -0.14 | -0.72 | -0.46 |
| 7 Days Ago | -0.23 | -0.14 | -0.69 | -0.55 |
| 30 Days Ago | -0.47 | -0.35 | -1.48 | -1.09 |
| 60 Days Ago | -0.47 | -0.35 | -1.48 | -1.09 |
| 90 Days Ago | -0.4 | -0.35 | -1.42 | -1.09 |
EPS Revisions
| CURRENCY IN USD | Current Qtr. (Mar 2024) | Next Qtr. (Jun 2024) | Current Year (2024) | Next Year (2025) |
|---|---|---|---|---|
| Up Last 7 Days | -- | -- | -- | 1 |
| Up Last 30 Days | 1 | 2 | 3 | 3 |
| Down Last 7 Days | -- | -- | -- | -- |
| Down Last 30 Days | 1 | -- | 1 | -- |
Growth Estimates
| CURRENCY IN USD | ATRA | Industry | Sector | S&P 500 |
|---|---|---|---|---|
| Current Qtr. | 63.90% | -- | -- | 1.60% |
| Next Qtr. | 79.40% | -- | -- | 10.50% |
| Current Year | 72.40% | -- | -- | 5.20% |
| Next Year | 36.10% | -- | -- | 13.30% |
| Next 5 Years (per annum) | -- | -- | -- | 11.22% |
| Past 5 Years (per annum) | -- | -- | -- | -- |
Research Analysis
Analyst Price Targets
Fair Value
Fair Value is the appropriate price for the shares of a company, based on its earnings and growth rate also interpreted as when P/E Ratio = Growth Rate. Estimated return represents the projected annual return you might expect after purchasing shares in the company and holding them over the default time horizon of 5 years, based on the EPS growth rate that we have projected.
Analyst Recommendations
- Strong Buy
- Buy
- Hold
- Underperform
- Sell
Earnings
Upgrades & Downgrades
| Maintains | Stifel: Hold to Hold | 4/1/2024 |
| Maintains | Goldman Sachs: Sell to Sell | 11/10/2023 |
| Downgrade | Evercore ISI Group: Outperform to In-Line | 11/9/2023 |
| Downgrade | HC Wainwright & Co.: Buy to Neutral | 11/9/2023 |
| Downgrade | Mizuho: Buy to Neutral | 11/9/2023 |
| Reiterates | HC Wainwright & Co.: Buy to Buy | 9/26/2023 |
Related Tickers
FGEN FibroGen, Inc.
1.1500
-1.71%
ALLO Allogene Therapeutics, Inc.
3.4700
+0.29%
CTMX CytomX Therapeutics, Inc.
1.6700
-3.47%
ELEV Elevation Oncology, Inc.
3.8000
-5.24%
KPTI Karyopharm Therapeutics Inc.
1.1700
-8.59%
GTHX G1 Therapeutics, Inc.
4.1100
-1.44%
IMUX Immunic, Inc.
1.1800
-7.09%
BCAB BioAtla, Inc.
2.1050
-13.37%
PSTX Poseida Therapeutics, Inc.
2.0200
+1.00%
XLO Xilio Therapeutics, Inc.
1.1500
-10.16%